



To whom it may concern

**Dr. Stefan Dreiheller**  
Quality Unit / Regulatory Affairs

Date of issue: 02.02.2021  
Page 1/1  
Doc.-No. EIP-0055  
Revision 9

## Nanotechnology

MEGGLE Products:

- Lactose Monohydrate (Ph. Eur. / USP-NF / JP): CapsuLac<sup>®</sup> 60, FlowLac<sup>®</sup> 90, FlowLac<sup>®</sup> 100, GranuLac<sup>®</sup> 70, GranuLac<sup>®</sup> 80, GranuLac<sup>®</sup> 140, GranuLac<sup>®</sup> 200, GranuLac<sup>®</sup> 230, PrismaLac<sup>®</sup> 40, SacheLac<sup>®</sup> 80, SorboLac<sup>®</sup> 400, SpheroLac<sup>®</sup> 100, Tablettose<sup>®</sup> 70, Tablettose<sup>®</sup> 80, Tablettose<sup>®</sup> 100
- Lactose Monohydrate (USP-NF / Ph. Eur. / JP): Lactose monohydrate Low Endotoxin
- Inhaler Grade Lactose Monohydrate (USP-NF / Ph. Eur. / JP): InhaLac<sup>®</sup> 70, InhaLac<sup>®</sup> 120, InhaLac<sup>®</sup> 140, InhaLac<sup>®</sup> 150, InhaLac<sup>®</sup> 160, InhaLac<sup>®</sup> 230, InhaLac<sup>®</sup> 250, InhaLac<sup>®</sup> 251, InhaLac<sup>®</sup> 400, InhaLac<sup>®</sup> 500
- Co-processed excipients: Cellactose<sup>®</sup> 80, CombiLac<sup>®</sup>, MicroceLac<sup>®</sup> 100, RetaLac<sup>®</sup>, Reta M<sup>®</sup>, StarLac<sup>®</sup>

It is the aim of nanotechnology to achieve new material properties which were previously unknown via building up nanostructures in materials.


The products are not engineered to have at least one external dimension, or an internal or surface structure, in the nanoscale range (approximately 1 nm to 100 nm).

The products are not engineered to exhibit properties or phenomena, including physical or chemical properties or biological effects, that are attributable to its dimension(s), even if these dimensions fall outside the nanoscale range, up to one micrometer (1,000 nm).

Best regards

**MEGGLE GmbH & Co. KG**

represented by MEGGLE Verwaltungs GmbH

  
Dr. Stefan Dreiheller